| Methods |
Randomised, placebo‐controlled cross‐over trial of ramipril |
| Participants |
8 participants, mean age 34.4 years, range 19 to 45; 6 male |
| Interventions |
2.5 mg ramipril daily for 12 weeks versus placebo for 12 weeks. 4‐week washout |
| Outcomes |
Cycle ergometry, maximal workload, maximum heart rate and maximum oxygen uptake. 31P‐MRS calf during plantar flexion, SF‐36 and WHO‐DAS 11 |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
The method of randomisation was not described |
| Allocation concealment (selection bias) |
Unclear risk |
The method of allocation concealment was not described |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Both participants and observers were blinded |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
All 8 randomised participants were evaluated |
| Selective reporting (reporting bias) |
Unclear risk |
Data are reported equally for both treatment and placebo groups |
| Other bias |
Unclear risk |
Placebos were provided free of charge by the pharmaceutical company |
